Gritstone bio Statistics
Total Valuation
Gritstone bio has a market cap or net worth of $78.59 million. The enterprise value is $101.79 million.
| Market Cap | 78.59M |
| Enterprise Value | 101.79M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Gritstone bio has 106.40 million shares outstanding. The number of shares has increased by 27.07% in one year.
| Shares Outstanding | 106.40M |
| Shares Change (YoY) | +27.07% |
| Shares Change (QoQ) | +1.80% |
| Owned by Insiders (%) | 2.30% |
| Owned by Institutions (%) | 40.37% |
| Float | 90.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.81 |
| Forward PS | 5.52 |
| PB Ratio | 1.52 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.20, with a Debt / Equity ratio of 2.02.
| Current Ratio | 3.20 |
| Quick Ratio | n/a |
| Debt / Equity | 2.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -33.31 |
Financial Efficiency
Return on equity (ROE) is -147.20% and return on invested capital (ROIC) is -89.16%.
| Return on Equity (ROE) | -147.20% |
| Return on Assets (ROA) | -69.50% |
| Return on Capital (ROIC) | -89.16% |
| Revenue Per Employee | $70,753 |
| Profits Per Employee | -$599,524 |
| Employee Count | 231 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.37% in the last 52 weeks. The beta is 0.43, so Gritstone bio's price volatility has been lower than the market average.
| Beta (1Y) | 0.43 |
| 52-Week Price Change | -71.37% |
| 50-Day Moving Average | 1.93 |
| 200-Day Moving Average | 1.92 |
| Relative Strength Index (RSI) | 25.21 |
| Average Volume (30 Days) | 2,959,841 |
Short Selling Information
The latest short interest is 9.12 million, so 8.57% of the outstanding shares have been sold short.
| Short Interest | 9.12M |
| Short Previous Month | 8.82M |
| Short % of Shares Out | 8.57% |
| Short % of Float | 10.07% |
| Short Ratio (days to cover) | 4.95 |
Income Statement
In the last 12 months, Gritstone bio had revenue of $16.34 million and -$138.49 million in losses. Loss per share was -$1.20.
| Revenue | 16.34M |
| Gross Profit | 16.34M |
| Operating Income | -139.65M |
| Pretax Income | -138.49M |
| Net Income | -138.49M |
| EBITDA | -112.80M |
| EBIT | -134.45M |
| Loss Per Share | -$1.20 |
Balance Sheet
The company has $81.57 million in cash and $104.78 million in debt, giving a net cash position of -$23.20 million or -$0.22 per share.
| Cash & Cash Equivalents | 81.57M |
| Total Debt | 104.78M |
| Net Cash | -23.20M |
| Net Cash Per Share | -$0.22 |
| Equity / Book Value | 51.85M |
| Book Value Per Share | 0.49 |
| Working Capital | 60.10M |
Cash Flow
In the last 12 months, operating cash flow was -$121.65 million and capital expenditures -$4.57 million, giving a free cash flow of -$126.22 million.
| Operating Cash Flow | -121.65M |
| Capital Expenditures | -4.57M |
| Free Cash Flow | -126.22M |
| FCF Per Share | -$1.09 |
Margins
Gross margin is 100.00%, with operating and profit margins of -854.46% and -847.34%.
| Gross Margin | 100.00% |
| Operating Margin | -854.46% |
| Pretax Margin | -847.34% |
| Profit Margin | -847.34% |
| EBITDA Margin | -690.16% |
| EBIT Margin | -822.65% |
| FCF Margin | -772.27% |
Dividends & Yields
Gritstone bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.07% |
| Shareholder Yield | -27.07% |
| Earnings Yield | -176.23% |
| FCF Yield | -160.61% |
Analyst Forecast
The average price target for Gritstone bio is $6.33, which is 757.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.33 |
| Price Target Difference | 757.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 80.10% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gritstone bio has an Altman Z-Score of -6.82 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.82 |
| Piotroski F-Score | 1 |